MedPath

Citrulline

Generic Name
Citrulline
Drug Type
Small Molecule
Chemical Formula
C6H13N3O3
CAS Number
372-75-8
Unique Ingredient Identifier
29VT07BGDA

Overview

Citrulline is an amino acid. It is made from ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle. It is also produced from arginine as a by-product of the reaction catalyzed by NOS family. Its name is derived from citrullus, the Latin word for watermelon, from which it was first isolated.

Background

Citrulline is an amino acid. It is made from ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle. It is also produced from arginine as a by-product of the reaction catalyzed by NOS family. Its name is derived from citrullus, the Latin word for watermelon, from which it was first isolated.

Indication

Used for nutritional supplementation, also for treating dietary shortage or imbalance.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis
2025/05/25
NCT06989567
Phase 3
Not yet recruiting
Asklepion Pharmaceuticals, LLC
Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease
2024/10/10
NCT06635902
Phase 2
Recruiting
Suvankar Majumdar
Novel Approaches for Improving Vascular Function in Veterans With HFpEF
2024/03/15
NCT06312748
Phase 1
Recruiting
VA Office of Research and Development
Oral Citrulline Supplementation in COPD Patients With Malnutrition
2024/01/19
NCT06212765
Phase 3
Not yet recruiting
University Hospital, Grenoble
Study to Improve Deployment Related Asthma by Using L-Citrulline Supplementation
2022/03/02
NCT05259904
Phase 2
Recruiting
University of Colorado, Denver
A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects
2022/02/23
NCT05253209
Phase 3
Recruiting
Asklepion Pharmaceuticals, LLC
Role of L-citrulline in Prevention of Pregnancy Associated Hypertension
2021/07/28
NCT04979793
Phase 1
Suspended
The University of Texas Medical Branch, Galveston
L-citrulline Injection in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting With Vaso-Occlusive Crisis (VOC)
2021/04/21
NCT04852172
Phase 1
Recruiting
Asklepion Pharmaceuticals, LLC
Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19
2020/09/30
NCT04570384
Phase 2
Completed
Asklepion Pharmaceuticals, LLC
L-Citrulline Dose Finding Safety Study in MELAS
2019/05/16
NCT03952234
Phase 1
Completed
Baylor College of Medicine

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Lipovite
Perdido Key Health and Wellness Inc
70104-128
INTRAMUSCULAR
1 mg in 1 mL
11/23/2015

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy